Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine : A pharmacologically based regimen

摘要: BACKGROUND Although chemotherapy can achieve a high rate of disease remission induction in patients with newly diagnosed acute myelogenous leukemia (AML), recurrent or refractory AML generally have poorer response. This study assessed the utility mitoxantrone and intermediate-dose cytarabine (Ara-C) treatment AML. METHODS Forty-seven were treated Ara-C, 0.5 gm/m2, intravenously (i.v.) every 12 hours × doses on Days 1–6 mitoxantrone, 5 mg/m2, i.v. 1–5. RESULTS Twenty-nine 47 (62%) achieved complete The median duration was 112 days (range, 29 days–8 years). Of 25 age ≥ 60 years, 19 (76%) had this group 114 33–370 days), although all subsequently developed recurrence. well tolerated, mean neutropenia 31 thrombocytopenia 33 days. Three died infectious complications between 23–26 after initiation chemotherapy, 1 patient sudden cardiac arrest 13 cutaneous desquamation. cerebellar dysfunction. CONCLUSIONS The use Ara-C is effective AML. subgroup years also regimen, regimen tolerated. Cancer 2000;88:2037–41. © 2000 American Society.